Zentalis Regains Worldwide Development and Commercialization Rights to Azenosertib, ZN-d5 and ZN-c5 As a Result of Termination of Greater China Collaboration and License Agreements
Portfolio Pulse from Charles Gross
Zentalis Pharmaceuticals has terminated its Collaboration and License Agreements with Zentera Therapeutics, regaining worldwide development and commercialization rights to azenosertib, ZN-d5, and ZN-c5 in Greater China. Zentalis will pay Zentera $30 million upfront, a milestone payment, and a low single-digit royalty on net sales.
June 15, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zentalis Pharmaceuticals regains worldwide rights to azenosertib, ZN-d5, and ZN-c5 in Greater China after terminating agreements with Zentera Therapeutics.
The termination of the agreements allows Zentalis to regain control over the development and commercialization of its product candidates in Greater China, which could potentially lead to increased revenues and market share. The upfront payment of $30 million to Zentera may have a short-term negative impact on Zentalis' cash position, but the regained rights could outweigh this in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100